Key result
Adding a combination of lipocalin-2, A-FABP, and FGF-19 to conventional clinical risk factors improved the area under the curve for predicting MACE from 0.68 to 0.75 in patients with stable CAD.
Why the study?
Does a panel of cardiometabolic biomarkers (lipocalin-2, A-FABP, FGF-19) improve the prediction of MACE compared to conventional risk factors in patients with stable coronary artery disease?
Population
2,428 Chinese patients with stable coronary artery disease, comprising a discovery cohort and a validation…
Comparison
Age-biomarkers-clinical risk factor model… vs Conventional risk factors alone or age-clinical…
Design
Cohort
Follow-up
median 35 months
Authors
Loading...
May refine MACE risk stratification in stable CAD; leaves open prospective validation before clinical use.
Cohort (n=2,428)
Does a panel of cardiometabolic biomarkers (lipocalin-2, A-FABP, FGF-19) improve the prediction of MACE compared to conventional risk factors in patients with stable coronary artery disease?
Hazard Ratio: 2.23 (95% CI 1.62–3.08)
A novel risk prediction model incorporating lipocalin-2, A-FABP, and FGF-19 significantly improves the discrimination of future MACE in patients with stable coronary artery disease.
Wong et al. (2018) conducted a cohort in Stable coronary artery disease (n=2,428). Biomarker panel (lipocalin-2, A-FABP, and FGF-19) vs. Conventional clinical risk factors alone was evaluated on New-onset major adverse cardiovascular events (MACE) (HR 2.23, 95% CI 1.62-3.08). Adding a combination of lipocalin-2, A-FABP, and FGF-19 to conventional clinical risk factors improved the area under the curve for predicting MACE from 0.68 to 0.75 in patients with stable CAD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: